Research libraryPeptide science basics
Peptides and Polypeptides: Structure, Synthesis and Characterization
For laboratory research use only. The compounds discussed here are sold strictly for in vitro research. They are not drugs, supplements or cosmetics and are not for human or animal use. This article summarizes published literature for reference and is not medical or usage advice.
Ask three chemists where a peptide stops and a protein starts and you’ll get three answers, all of them defensible. Peptides and polypeptides are the same chemistry anyway: amino acids strung together by amide bonds, with the sequence doing most of the work. We care about the practical end of it. How the chain gets built, how anyone proves it’s the molecule on the label, and how quickly it falls apart once it’s wet. Every claim below links to the paper it came from.
Key findings
- Pauling, Corey and Branson described the alpha helix in 1951 from the geometry of the amide bond alone, before any protein structure had been solved [1].
- Sanger’s group settled the amide groups of insulin in 1955, the work that made full sequences possible [2].
- Fmoc solid phase synthesis is now the default route to synthetic peptides, and multi ton production of peptide drugs is what made the building blocks cheap [3].
- By 2018 Lau and Dunn counted over 60 approved peptide drugs across the US and other major markets, plus 150-odd still in development [4].
- Insulin was the first, about a century back. More than 80 peptide drugs have followed it to market [5].
- Asparagine deamidation rates were measured across 306 asparaginyl sequences in model peptides at pH 7.4 and 37 degrees C, and they vary enormously with the neighbouring residue [8].
What actually counts as a peptide
Amino group one end, carboxyl the other. Stick the carboxyl of one onto the amino of the next, kick out a water molecule, and that’s your amide bond, which in this context everybody calls a peptide bond. Repeat until bored. The chain has a direction, written N terminus to C terminus, and the direction counts: Ala-Gly and Gly-Ala are not the same molecule.
Convention sticks chains of roughly 2 to 50 residues in the peptide bucket, longer ones in the polypeptide or protein bucket. Treat that as a habit, not a rule. Insulin runs about 51 residues over its two chains, and depending who you ask it’s a protein or a peptide hormone. That’s how soft the line is.
The bond itself is where things get interesting. Electrons smear across the carbonyl and the nitrogen, the bond picks up partial double bond character, and rotation around it mostly stops, leaving six atoms sitting nearly flat. So every conformational move a chain makes happens at the two bonds flanking that rigid plate. Pauling, Corey and Branson built the alpha helix out of exactly this constraint plus hydrogen bonding, and published it in 1951 with no experimental structure in hand [1]. The helix they predicted turned out to be right.
Sequence, and the layers built on top of it
Primary structure is just the residue order. Sounds trivial. It’s actually the whole game, since helices, sheets, turns, the tertiary fold and any multi chain assembly all come out of that sequence plus whatever solvent it’s sitting in.
Below roughly 15 residues, peptides mostly don’t hold one fold in water. They flicker through a pile of conformations and only settle when a binding partner or a membrane gives them a reason to. Keep that in mind with older papers that talk about “the structure” of some small peptide as if it were a statue.
Some side chains matter far more than others here:
- Cysteines pair up into disulfide bridges that staple the chain to itself, and stability changes completely once they do.
- Proline drags a ring onto the backbone and loses you a hydrogen bond donor, so helices tend to break there and turns show up.
- Charge, at the termini and on the side chains, drives solubility. It’s why the same molecule acts like a different one at pH 4 and pH 8.
Sanger’s insulin work is where this stopped being speculation. Sorting out which glutamate and aspartate positions were actually amides was painstaking chemistry, and it gave the field its first complete sequence of a natural polypeptide [2]. For a longer look at where molecules like this come from, we wrote up the difference between natural and synthetic peptides separately.
How synthetic peptides get made
Near enough every synthetic peptide comes off a solid support. The chain sits anchored to a resin bead; each round bolts on one protected amino acid, then strips the temporary group off the new N terminus so the next can go on. Here’s the trick that makes it work: because the product is glued to the bead, you can just wash the excess reagent away instead of purifying after every step.
Two chemistries dominate the protecting group choice, Boc and Fmoc. Fmoc won. Behrendt and colleagues put it plainly: Fmoc solid phase synthesis is the method of choice today, high quality building blocks are cheap because peptide drugs are now made by the ton, and a wide range of modified residues can be bought off the shelf as Fmoc derivatives [3]. Chain assembly is only half of it, though. Cleavage from the resin, global deprotection, preparative chromatography and lyophilisation all happen afterwards, and each step can cost you material.
Long sequences get harder, not linearly but steeply. Every coupling is less than perfect, deletion sequences accumulate, and aggregation on the resin can stall the chain outright. Past roughly 50 residues, people start stitching fragments together or switch to recombinant expression.
Why anyone bothers
Peptides sit in an odd middle ground. They are far more selective than small molecules, because they can bury a large contact surface, and they are far less of a manufacturing headache than antibodies. The counterweight is that they are chewed up by proteases, cleared quickly, and poorly absorbed from the gut. Fosgerau and Hoffmann’s summary from 2015 is still a fair statement of the balance, and noted around 140 peptide candidates in clinical trials at the time [6]. Lau and Dunn counted over 60 approved peptide drugs in the United States and other major markets and more than 150 in active development [4]. Muttenthaler and co-authors put the century long tally at more than 80 approved peptide drugs and traced how the sources shifted from human hormones to venoms and display libraries [5].
Proving a peptide is the peptide
A white powder tells you nothing at all. Identity and purity come from two orthogonal measurements, and a lab running only one of them is handing you half a story.
| Method | What it answers | What it misses |
|---|---|---|
| Reversed phase HPLC | How much of the material is the main species, by peak area | Co-eluting impurities of similar hydrophobicity |
| Mass spectrometry | Whether the molecular weight matches the intended sequence | Isomers and some deletions of identical mass |
| MS/MS sequencing | The actual residue order, read from fragment ions | Little, which is why it is the reference method |
| Water and counterion content | How much of the vial weight is not peptide | Nothing about sequence |
Tandem mass spectrometry does the heavy lifting. Aebersold and Mann’s review lays out how fragmentation patterns identify and quantify peptides from complex mixtures, which is the same principle applied to a single synthetic product [7]. HPLC purity and MS identity together are the backbone of a certificate of analysis; you can see what a full set looks like on our COA page, and we go deeper into testing in our write up on third party tested material.
Here’s the number people misread constantly: net peptide content. A vial reading 98 percent pure by HPLC can sit well under 98 percent peptide by mass, because water and trifluoroacetate counterions hitch a ride out of purification. Purity and content answer different questions.
Stability, which is where most material goes wrong
Peptides fall apart chemically, not only microbially. Asparagine and glutamine deamidate, and how fast depends enormously on the residue sitting next door. Robinson and Robinson measured deamidation across 306 asparaginyl sequences in model peptides at pH 7.4 and 37 degrees C and found a spread wide enough that they proposed the reaction works as a biological timer [8]. Aspartate isomerisation, methionine and cysteine oxidation, and plain hydrolysis of the backbone all queue up behind it. Manning and colleagues’ update on protein pharmaceutical stability covers the same degradation routes along with the physical ones, aggregation and surface adsorption included [9].
Practical consequences, roughly in order of how often they bite:
- Lyophilised solid stored cold keeps far better than anything in solution.
- pH matters more than most people expect, and the worst pH is not the same for every sequence.
- Repeated freezing and thawing loses you material to aggregation and to the container walls, chemistry aside.
- Dilute solutions stick to plastic. On an assay that looks exactly like degradation, and it isn’t.
The absorption problem
Peptides taken by mouth face acid, proteases and an epithelium built to keep large molecules out. Oral bioavailability of unmodified peptides typically sits around or below 1 to 2 percent [10]. Drucker’s review walks through what has been tried against that: permeation enhancers, enzyme inhibitors, cell penetrating sequences, and the formulation work that led to the first oral GLP-1 receptor agonist tablet [10]. We cover that story in more detail in our piece on oral peptide absorption barriers.
Plenty of native sequences have half lives in minutes, same underlying weakness. The chemistry pushes back: D-amino acids at the cleavage sites, acetylation at the N terminus, amidation at the C terminus, cyclisation, fatty acid or polymer conjugation. All of those change the molecule. A modified analogue is its own compound with its own characterisation work, not the parent with an upgrade bolted on.
Classes you will meet
Grouping by chemistry rather than by what anyone hopes a molecule does:
| Class | Defining feature | Example |
|---|---|---|
| Linear peptides | Free N and C termini, often amidated | Most synthetic analogues |
| Cyclic peptides | Head to tail or side chain ring closure, more protease resistant | Many natural product peptides |
| Disulfide rich peptides | Multiple cysteine bridges fixing a compact fold | Venom derived sequences [5] |
| Conjugates | Peptide plus a polymer, lipid or payload | PEGylated and acylated analogues |
FAQ
What is the difference between a peptide and a protein?
Chain length and convention. Short chains are called peptides, longer folded ones proteins, with the cut usually placed near 50 residues. The bond chemistry is identical.
Why do synthetic peptides come as a lyophilised powder?
Because water drives most of the degradation chemistry. Removing it before storage slows deamidation, hydrolysis and oxidation by a large margin [9].
Does 99 percent purity mean 99 percent peptide by weight?
No. HPLC purity measures the fraction of peptide related material that is the target species. Water and counterions are separate, and net peptide content is reported separately on a proper certificate of analysis.
References
- Pauling L, Corey RB, Branson HR. The structure of proteins: two hydrogen-bonded helical configurations of the polypeptide chain. Proc Natl Acad Sci U S A. 1951. PMID 14816373
- Sanger F, Thompson EO, Kitai R. The amide groups of insulin. Biochem J. 1955. PMID 14363129
- Behrendt R, White P, Offer J. Advances in Fmoc solid-phase peptide synthesis. J Pept Sci. 2016. PMID 26785684
- Lau JL, Dunn MK. Therapeutic peptides: historical perspectives, current development trends, and future directions. Bioorg Med Chem. 2018. PMID 28720325
- Muttenthaler M, King GF, Adams DJ, Alewood PF. Trends in peptide drug discovery. Nat Rev Drug Discov. 2021. PMID 33536635
- Fosgerau K, Hoffmann T. Peptide therapeutics: current status and future directions. Drug Discov Today. 2015. PMID 25450771
- Aebersold R, Mann M. Mass spectrometry-based proteomics. Nature. 2003. PMID 12634793
- Robinson NE, Robinson AB. Molecular clocks. Proc Natl Acad Sci U S A. 2001. PMID 11158575
- Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010. PMID 20143256
- Drucker DJ. Advances in oral peptide therapeutics. Nat Rev Drug Discov. 2020. PMID 31848464